FibroGen Inc (FGEN)
0.6508
+0.03
(+4.23%)
USD |
NASDAQ |
Jan 08, 16:00
0.65
0.00 (0.00%)
After-Hours: 20:00
FibroGen SG&A Expense (Quarterly): 17.55M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 253.50M |
| Arbutus Biopharma Corp | 4.537M |
| GlycoMimetics Inc | 4.006M |
| Cidara Therapeutics Inc | 4.965M |
| Cue Biopharma Inc | 2.867M |